SEC Form 10-Q filed by Repare Therapeutics Inc.
$RPTX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/9/2023 | $11.00 → $16.00 | Hold → Buy | Stifel |
| 2/3/2023 | $28.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/6/2023 | $28.00 | Overweight | CapitalOne |
| 4/12/2022 | $11.00 | Buy → Hold | Stifel |
| 3/17/2022 | $43.00 | Buy | Goldman |
| 9/23/2021 | $48.00 | Buy | Stifel |
| 9/13/2021 | $54.00 | Buy | HC Wainwright & Co. |
| 8/16/2021 | $45.00 → $47.00 | Overweight | Morgan Stanley |
Combines cancer biology, genetics, medicinal chemistry, and biologics research and development experience to rapidly advance a broad pipeline of preclinical oncology programs against genetically-defined cancers Licenses Repare's SNIPRx®, SNIPRx-surf, and STEP2 platforms for discovering druggable intracellular and synergistic cell-surface targets and identifying small molecules sensitive to specific cancer lesions Licenses preclinical small molecule and antibody programs for developing antibody drug conjugates Supported by DCx's co-founding investor, Amplitude Ventures, to create a leading company in developing differentiated first-in-class precision drug conjugates DCx Biotherapeut
Repare Therapeutics Inc. ("Repare") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation ("DCx"), a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment. "We have taken careful steps to evaluate all aspects of our business to ensure continued value generation,
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Ap
8-K - Repare Therapeutics Inc. (0001808158) (Filer)
8-K/A - Repare Therapeutics Inc. (0001808158) (Filer)
10-Q - Repare Therapeutics Inc. (0001808158) (Filer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)
3 - Repare Therapeutics Inc. (0001808158) (Issuer)
4 - Repare Therapeutics Inc. (0001808158) (Issuer)